SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination, 2024, Nguyen et al.

SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination
Nguyen, Doan C.; Hentenaar, Ian T.; Morrison-Porter, Andrea; Solano, David; Haddad, Natalie S.; Castrillon, Carlos; Runnstrom, Martin C.; Lamothe, Pedro A.; Andrews, Joel; Roberts, Danielle; Lonial, Sagar; Sanz, Ignacio; Lee, F. Eun-Hyung

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines are effective at protecting from severe disease, but the protective antibodies wane rapidly even though SARS-CoV-2-specific plasma cells can be found in the bone marrow (BM).

Here, to explore this paradox, we enrolled 19 healthy adults at 2.5–33 months after receipt of a SARS-CoV-2 mRNA vaccine and measured influenza-, tetanus-or SARS-CoV-2-specific antibody-secreting cells (ASCs) in long-lived plasma cell (LLPC) and non-LLPC subsets within the BM.

Only influenza-and tetanus-specific ASCs were readily detected in the LLPCs, whereas SARS-CoV-2 specificities were mostly absent. The ratios of non-LLPC:LLPC for influenza, tetanus and SARS-CoV-2 were 0.61, 0.44 and 29.07, respectively. In five patients with known PCR-proven history of recent infection and vaccination, SARS-CoV-2-specific ASCs were mostly absent from the LLPCs. We show similar results with measurement for secreted antibodies from BM ASC culture supernatant. While serum IgG titers specific for influenza and tetanus correlated with IgG LLPCs, serum IgG levels for SARS-CoV-2, which waned within 3–6 months after vaccination, were associated with IgG non-LLPCs.

In all, our studies suggest that rapid waning of SARS-CoV-2-specific serum antibodies could be accounted for by the absence of BM LLPCs after these mRNA vaccines.

Link | PDF (Nature Medicine) [Open Access]

 

'Hybrid immunity' was promoted as a verified fact. By simply asserting it. As it turns out, wishes don't become reality just because it would be handy if they did. So all immunity to COVID is short-lived, and the virus is both wildly mutating and highly contagious. So it's just a question of when a variant causes as much trouble as the original one. Could be a long while. Could be shortly. Almost all policies maximize this outcome, so whether it's sooner or later, choices made will make it sooner regardless.

And no one will suffer any credibility loss from this. In part because it spread like wildfire among the laptop class and was adopted with zero evidence, making pretty much everyone guilty, which means no one is. And the same people who botched this pandemic will botch the next one just as bad, but with far worse starting conditions. "Trust us, we're experts", they'll say, as they make every single mistake they made before all over again.

 

Interesting. Small study population, though (n=19); also curious about the LLPC subset definition ("localized the BM LLPC compartment into PopD (CD19- CD38hi CD138+)" - is there really certainty that the other subsets are not long-lived, why only the CD19- subset? Wonder if they plan to follow up by testing w/ vaccination using alternative platforms like the protein-subunit Novavax (not sure if there are any Western viral-vector ones left after the withdrawal of AstraZeneca)

 

Probably doesn't matter, T-cell memory is there and is what prevents hospitalization and death

This was dicussed on the current episode TWIV--microbe TV episode with Dr. Daniel Griffin and virologist Vincent Rancaniello.